Literature DB >> 8177045

Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia.

M M Ritter1, H C Geiss, W O Richter, P Schwandt.   

Abstract

Lipoprotein(a) [Lp(a)] concentrations are known to be stable under various dietary and drug regimens. Little is known about the influence of hyperlipoproteinemia on Lp(a) levels. Therefore, we investigated Lp(a) concentrations and apolipoprotein(a) [apo(a)] polymorphism in 147 patients with hypertriglyceridemia and in 93 patients with hypercholesterolemia and compared them with 404 subjects without hyperlipoproteinemia (controls). Despite a similar apo(a) isoform and phenotype distribution, Lp(a) concentrations differed significantly (P < .0001) between the three groups. The median Lp(a) level in control subjects was 17 mg/dL (mean, 38 mg/dL), compared with 38 mg/dL (mean, 56 mg/dL) in patients with hypercholesterolemia and 9 mg/dL (mean, 21 mg/dL) in those with hypertriglyceridemia. These differences persisted after exclusion of 61 subjects with coronary heart disease. The inverse correlation between the molecular weight of the apo(a) isoforms and the Lp(a) concentration was preserved within each group (P < .001), but for every molecular weight range studied the level of Lp(a) was always higher in patients with hypercholesterolemia and always lower in those with hypertriglyceridemia than in controls. We conclude that hypertriglyceridemia or hypercholesterolemia have profound--but divergent--influences on the concentration of Lp(a).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177045     DOI: 10.1016/0026-0495(94)90198-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  Lipoprotein (a) metabolism estimated by nonsteady-state kinetics.

Authors:  K G Parhofer; T Demant; M M Ritter; H C Geiss; M Donner; P Schwandt
Journal:  Lipids       Date:  1999-04       Impact factor: 1.880

2.  Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.

Authors:  S Takahashi; T Yamamoto; Y Moriwaki; Z Tsutsumi; K Higashino
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

3.  Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.

Authors:  C Otto; K G Parhofer; M M Ritter; W O Richter; P Schwandt
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

4.  Lipoprotein(a) and cardiovascular risk factors in a cohort of 6-year-old children. The Rivas-Vaciamadrid Study.

Authors:  Angel Gonzalez-Requejo; Marciano Sanchez-Bayle; Consuelo Ruiz-Jarabo; Juliana Asensio-Anton; Maria Jesus Pelaez; Maria Teresa Morales; Epifania Anton-Pacheco; Margarita Fernandez-Calle; Elsa Madera-Cruz
Journal:  Eur J Pediatr       Date:  2003-06-19       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.